![]() | |
![]() | |
Clinical data | |
---|---|
Other names | 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard(EPA) | |
ECHA InfoCard | 100.164.683![]() |
Chemical and physical data | |
Formula | C14H16ClN3O |
Molar mass | 277.75 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
JNJ-7777120 was a drug being developed byJohnson & Johnson Pharmaceutical Research & Development which acts as a potent and selectiveantagonist at thehistamine H4 receptor.[1] It hasanti-inflammatory effects,[2] and has been demonstrated to be superior to traditional (H1) antihistamines in the treatment ofpruritus (itching).[3] The drug was abandoned because of its shortin vivohalf-life andhypoadrenocorticism toxicity in rats and dogs, that prevented advancing it into clinical studies.[4]
![]() | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |